Molecular persistence at the end of consolidation and molecular and clinical relapse according to relapse risk group in LPA96 and LPA99 trials
. | Molecular persistence . | . | Molecular relapse . | . | Clinical relapse . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Relapse risk group and type of consolidation . | No. (%) . | No./tested . | No. . | Time to relapse, mo . | No. (CNS) . | Time to relapse, mo . | |||
| Low | 79 (21) | 0/72 | 1 | 16 | 2 (0) | 32, 39 | |||
| LPA96 study | 33 | 0 | 0 | — | 2 (0) | 32, 39 | |||
| LPA99 study | 46 | 0 | 1 | 16 | 0 | — | |||
| Intermediate | 208 (54) | 1/199 | 5 | 8-21 | 8 (2) | 8-31 | |||
| LPA96 study | 86 | 1 | 4 | 8-21 | 7 (2) | 8-31 | |||
| LPA99 study | 122 | 0 | 1 | 15 | 1 (0) | 19 | |||
| High | 97 (25) | 6/88 | 4 | 5-31 | 12 (4) | 4-32 | |||
| LPA96 study | 38 | 4 | 3 | 5-31 | 6 (3) | 4-14 | |||
| LPA99 study | 59 | 2 | 1 | 9 | 6 (1) | 4-32 | |||
| Overall | 384 | 7/359 | 10 | 5-31 | 22 (6) | 4-39 | |||
| LPA96 study | 157 | 5 | 7 | 5-31 | 15 (5) | 4-39 | |||
| LPA99 study | 227 | 2 | 3 | 9, 15 | 7 (1) | 4-32 | |||
. | Molecular persistence . | . | Molecular relapse . | . | Clinical relapse . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Relapse risk group and type of consolidation . | No. (%) . | No./tested . | No. . | Time to relapse, mo . | No. (CNS) . | Time to relapse, mo . | |||
| Low | 79 (21) | 0/72 | 1 | 16 | 2 (0) | 32, 39 | |||
| LPA96 study | 33 | 0 | 0 | — | 2 (0) | 32, 39 | |||
| LPA99 study | 46 | 0 | 1 | 16 | 0 | — | |||
| Intermediate | 208 (54) | 1/199 | 5 | 8-21 | 8 (2) | 8-31 | |||
| LPA96 study | 86 | 1 | 4 | 8-21 | 7 (2) | 8-31 | |||
| LPA99 study | 122 | 0 | 1 | 15 | 1 (0) | 19 | |||
| High | 97 (25) | 6/88 | 4 | 5-31 | 12 (4) | 4-32 | |||
| LPA96 study | 38 | 4 | 3 | 5-31 | 6 (3) | 4-14 | |||
| LPA99 study | 59 | 2 | 1 | 9 | 6 (1) | 4-32 | |||
| Overall | 384 | 7/359 | 10 | 5-31 | 22 (6) | 4-39 | |||
| LPA96 study | 157 | 5 | 7 | 5-31 | 15 (5) | 4-39 | |||
| LPA99 study | 227 | 2 | 3 | 9, 15 | 7 (1) | 4-32 | |||
CNS indicates central nervous system; and —, not applicable.